Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | MTAP | Q13126 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | UGCG | Q16739 | 2/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447027 | 0.88 | GBA1 (0.40) | BCHEACHETACR1PDPK1MTOR | |
| SCHEMBL18587328 | 0.79 | AGTR2 (0.47) | AGTR2NR1D1ABHD6DAGLAGBA1 | |
| SCHEMBL2914271 | 0.77 | BCHE (0.43) | AGTR2BCHEACHENR1D1ABHD6 | |
| SCHEMBL20484804 | 0.77 | AGTR2 (0.46) | AGTR2NR1D1ABHD6DAGLA | |
| SCHEMBL18588189 | 0.77 | AGTR2 (0.46) | AGTR2NR1D1ABHD6DAGLA | |
| SCHEMBL18587895 | 0.74 | AGTR2 (0.47) | AGTR2ACHENR1D1 | |
| SCHEMBL441959 | 0.74 | BCHE (0.42) | AGTR2BCHEACHENR1D1ABHD6 | |
| SCHEMBL20485026 | 0.72 | AGTR2 (0.42) | AGTR2NR1D1ABHD6DAGLA | |
| SCHEMBL23908558 | 0.71 | AGTR2 (0.45) | AGTR2NR1D1ABHD6DAGLA | |
| SCHEMBL17610289 | 0.71 | ABCB1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | AGTR2 1804/4885BCHE 1409/4885ACHE 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.